文献速递抗栓抗凝管理特殊人群用药

撒哈拉以南非洲黑人患者华法林起始剂量模型开发与验证

Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda.
PubMed 文献 · Clin Pharmacol Ther · 2020-12-28

本研究基于乌干达和南非364例患者开发华法林起始剂量模型,并在IWPC数据集的690例黑人患者中验证。最终模型纳入年龄、体重、目标INR范围和HIV状态四个预测因子,开发队列和验证队列的平均绝对误差分别为11.6和12.5 mg/周,较固定起始剂量分别降低7.5%和11.9%的高风险抗凝患者比例。

要点

  • 模型仅含年龄、体重、目标INR范围和HIV状态四个临床预测因子
  • 开发队列MAE为11.6 mg/周,验证队列MAE为12.5 mg/周
  • 较固定起始剂量,模型降低高风险抗凝患者比例7.5%和11.9%

核心结论

  • 开发并验证了首个针对乌干达和南非黑人患者的华法林起始剂量临床模型,其预测误差与IWPC和Gage模型相当,且较固定起始剂量降低高风险抗凝患者比例。

研究设计与样本

  • 开发队列纳入乌干达和南非8个门诊及医院科室的364例患者(2018年6月至2019年7月),验证队列使用IWPC数据集中的690例黑人患者。

主要发现

  • 最终模型纳入年龄、体重、目标INR范围和HIV状态四个预测因子。
  • 开发队列和验证队列的MAE分别为11.6(95%CI 10.4-12.8)和12.5(95%CI 11.6-13.4)mg/周。
  • 开发队列中IWPC和Gage模型的MAE分别为12.5(95%CI 11.3-13.7)和12.7(95%CI 11.5-13.8)mg/周。
  • 验证队列中IWPC和Gage模型的MAE分别为12.1(95%CI 11.2-13.0)和12.2(95%CI 11.4-13.1)mg/周。
  • 较固定起始剂量,本模型在开发队列和验证队列中分别降低高风险抗凝患者比例7.5%(1.5-13.7%)和11.9%(7.1-16.8%)。

临床怎么用

  • 对于撒哈拉以南非洲黑人患者,可基于年龄、体重、目标INR范围和HIV状态使用该模型估算华法林起始剂量。
  • 该模型较固定起始剂量可能减少抗凝不达标高风险患者比例,但临床效用尚待前瞻性研究验证。

局限性

  • 模型的临床效用将在前瞻性研究中检验,当前证据来自回顾性开发与验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Warfarin remains the oral anticoagulant of choice in sub-Saharan Africa. However, dosing is challenging due to a highly variable clinical response for a given dose. This study aimed to develop and validate a clinical warfarin dose-initiation model in sub-Saharan Black-African patients. For the development cohort, we used data from 364 patients who were recruited from 8 outpatient clinics and hospital departments in Uganda and South Africa (June 2018-July 2019). Validation was undertaken using the International Warfarin Pharmacogenetics Consortium (IWPC) dataset (690 black patients). Four predictors (age, weight, target International Normalized Ratio range, and HIV status) were included in the final model, which achieved mean absolute errors (MAEs; mean of absolute differences between true dose and dose predicted by the model) of 11.6 (95% confidence interval (CI) 10.4-12.8) and 12.5 (95% CI 11.6-13.4) mg/week in the development and validation cohorts, respectively. Two other clinical models, IWPC and Gage, respectively, obtained MAEs of 12.5 (95% CI 11.3-13.7) and 12.7 (95% CI 11.5-13.8) mg/week in the development cohort, and 12.1 (95% CI 11.2-13.0) and 12.2 (95% CI 11.4-13.1) mg/week in the validation cohort. Compared with fixed dose-initiation, our model decreased the percentage of patients at high risk of suboptimal anticoagulation by 7.5% (1.5-13.7%) and 11.9% (7.1-16.8%) in the development and validation cohorts, respectively. The clinical utility of this model will be tested in a prospective study. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? ☑ Warfarin dosing remains challenging due to a highly variable clinical response for a given dose. WHAT QUESTION DID THIS STUDY ADDRESS? ☑ Can a clinical dose-initiation model be developed and validated for sub-Saharan Black-African patients? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? ☑ We have developed the first warfarin dose-initiation clinical model for Black-African patients in Uganda and South Africa. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? ☑ We will be implementing and validating this model in a prospective cohort to inform future large-scale implementation. More optimized dosing should improve the quality of warfarin anticoagulation in these two developing countries.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Asiimwe IG, Waitt C, Sekaggya-Wiltshire C, et al. Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda. Clin Pharmacol Ther. 2020. PMID: 33280090. doi:10.1002/cpt.2128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。